PAK6: a potential anti-cancer target

Autores

DOI:

https://doi.org/10.1590/s2175-97902019000318315

Palavras-chave:

PAK6, androgen Receptor (AR), cancer therapy, miRNAs

Resumo

p21-activated kinase 6 (PAK6) is a member of the PAK family of serine/threonine kinases that are known effectors of Rho GTPases Cdc42 and Rac. PAKs regulate a large number of complex cellular mechanisms, including cell motility, morphology, and tumor development. PAK6, initially cloned as an interacting partner of the androgen receptor (AR), is associated with an array of cellular processes implicated in tumor progression. However, the full biological implications of PAK6 activity during cancer remain poorly understood. In this review, we assess our current understanding of the physiological roles of classical PAK6 functionality in mammals, in addition to its emerging role in tumorigenesis.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

Downloads

Publicado

2020-12-09

Edição

Seção

Revisão

Como Citar

PAK6: a potential anti-cancer target. (2020). Brazilian Journal of Pharmaceutical Sciences, 56, e18315. https://doi.org/10.1590/s2175-97902019000318315